Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

An Oxford University study has found that reducing the tendency of vitamin A to form toxic clumps could slow down a condition that leads to blindness in children and young adults.

Central retina of a teenage girl diagnosed with Stargardt disease, as seen by an ophthalmologist. The orange colour is partly due to vitamin A bound to visual proteins. Areas of lighter and/or darker orange are present throughout the retina and are indicative of the disease process.
Central retina of a teenage girl diagnosed with Stargardt disease, as seen by an ophthalmologist. The orange colour is partly due to vitamin A bound to visual proteins. Areas of lighter and/or darker orange are present throughout the retina and are indicative of the disease process.
Stargardt disease affects many children I see in my clinic and ABCA4-related retinal degenerations are also common in adults. The finding that a safe and simple dietary modification may help them is extremely promising. Dr Charbel Issa is to be congratulated for undertaking this incredibly detailed analysis that has provided further scientific validation of inhibiting vitamin A dimerization in this disease. We look forward to the next step of clinical trials.
- Professor Robert MacLaren, project supervisor

People usually associate vitamin A as being good for the eyes, but the study found that in patients with Stargardt disease, vitamin A transforms into toxic compounds, which cause chronic inflammation, premature ageing of the retina and vision loss.

Stargardt disease affects around 1 in 10,000 people and begins in childhood, leading to progressive loss of central vision. The condition is linked to defects on a gene known as ABCA4. In Stargardt disease, the light-sensitive tissue in the back of the eye - the retina - ages prematurely and granules called ‘lipofuscin’ accumulate.

To date, there is no treatment for Stargardt disease, but a team led by Oxford University DPhil student Peter Charbel Issa (now a Professor at the University of Bonn), used genetically engineered mice to look at one possible cause of the premature aging of the retina in Stargardt disease.

Read more on the University website...